hybridoma technology

hybridoma technology

2. KHURSHID ANWAR
BS BOTANY 8
TH

3. HYBRIDOM
A
TECHNOLO
GY

4. OBjECTIvES
•Hybridoma technology
•To understand concept behind production of monoclonal
Antibodies
•To understand various steps in production of hybridomas
•To understand method for preparation of hybridomas
•Role of hybridmas in plants
•Application of hybrdioma technology

5. DEfINITION

“Hybridoma technology is a method for
producing large numbers of identical 
antibodies (also called 
monoclonal antibodies)”

6. HYBRIDOMA
“Hybridoma is immortalized cell derived from
the fusion of B lymphoblast's with a myeloma
fusion partner”

7. TECHNOLGY
•“Technology
techniques, skills, met
hods,
and processes used in
the production
of goods or services o
r in the
accomplishment of
objectives, such
as scientific
investigation”

8. HISTORY
o Developed by Georges
J.F. Kohler and Cesar
Milstein in 1975
oThey shared nobel prize
for this discovery in 1984
oThe term hybridoma was
coined by Leonard
Herzenberg in 1975

9. PRINCIPLE
oThe hybrid cell has the capacity of antibody
production derived from B cells
oAt the same time it can divide continuously
by the quality derived from Myeloma cells
oBy combining the desired qualities of both
the cells, the technology ensures large scale
Antibody production of single specificity

10. WHAT ARE ANTIBODIES?
An antibody is a
protein used by
the immune
system to
identify and
neutralize
foreign objects
like bacteria and
viruses.

11. MONOCLONAL ANTIBODIES
•Monoclonal antibodies (mAb) are
antibodies that are identical because
they are produced by one type
of immune cell, all clones of a single
parent cell.

12. POLYCLONAL ANTIBODIES
•Polyclonal antibodies are derived
from different cell lines that differ
in amino acid sequence.

13. DIffERENCE

14. PRODUCTION Of MONOCLONAL
ANTIBODIES
•Mixture of fused and unfused cells
•Myeloma cells lack HGPRT or TK thus
produced in HAT medium Plan cells
•Colonial expansion

17. HAT MEDIUM

18. REqUIREMEnT of HybRIDoMA
lAb
•CO2 incubator
•Inverted microscope
•-78 `c deep freeze
•Centrifuge
•Liquid nitrogen container
•25 cm2 or 75 cm2 tissues cultures flask
•Penicillin and streptomycin

19. TIssUE cUlTURE flAsk
•Rectangular and have tilted
neck
•Designed to provide
maximum surface for
growth of cells.
•polypropylene or
polystyrene
•it have three size via
25cm, 75cm2 and 225 cm2

20. 96 WElls TIssUE cUlTURE
plATEs
•96 well plates and well flask
with bottom volume 400-500
micro liters
•Transparent and symmetrical
wells plates.
•wells plates are at defined
positions.
•8 rows and 12 columns
•well designed
•number e.g. A3,B5,C6 ,D4 etc

21. MyEloMA cEll cUlTURE
MEDIUM
•Cultured in RPMI-1640 or DMEM
•Basal medium containing 10 to 15% FCS.
•Basal medium contains salts, glucose, vitamins,
phenol red and calf serum.
•Penicillin and streptomycin.

22. pREpARATIon of RpMI-1640
•1 liter of medium is prepared by dissolving
following intergradient's in distilled water.
•RPMI-1640 1 vial
•NaHCO3 2-20 g
•HEPES 2-38 g
•Sod pyruvate 0.11 g
•Glutamine 0.57 g
•penicillin 100 U/ml
•streptomycin 0.10 g

23. MyEloMA cEll cUlTURE
•Revived from frozen stock or burrowed or purchased.
•Cells on arrival are fit with fresh basal medium.
•15 FCS & 5% co2 and 37'c
•Phenol red indicates the pH of the medium.
•If medium turns yellow and is transparent it indicates that
medium is to be replenished.
•If medium turns yellow and is turbid it indicates that bacterial
or fungal growth has occurred.

24. conT….
•Splitting cells 1:9 times with fresh medium.
•Confluence term is for extent surface
occupied by growing cell mass
•It is appropriate to sub-culture cells at
70-90 % confluence.

25. HARvEsTIng of MyEloMA
cElls
•Myeloma cells growing in log phase of 3rd
generation are used for fusion.
•Cells are centrifuged at 1000 ppm for
5minuts.
•Cells are counted after staining with trypan
blue dye.

27. cElls cUlTURE
conTAMInATIon
•Medium also support growth of bacteria
fungal and mycoplasma
•They divide at much faster rate then myeloma
cells
•Deplete nutrients very fast.
•Contaminations come from environment,
during culture handling and prepration of
medium.

28. sTEpWIsE pRocEDURE
•o Isolation of B cells
•-Mice , 2-4 weeks old are immunized with the
antigen against which monoclonal antibodies
are to be raised by subcutaneous injection
•-Later B cells are isolated from the spleen of
an immunized mouse

29. soMATIc cEll fUsIon
•-Electrofusion : cells are allowed to fuse
with the application of an electric field
•-Done by using PEG medium
•-PEG stands for Poly Ethylene Glycol

31. Selection of hybrid cellS
•-HAT medium is used for the selection
of hybrid cells
•-HAT stands for Hypoxanthine
Aminopterine Thymidine

32. how hAt medium workS in the
Selection of hybrid cellS
•-B cells are HGPRT+ and can survive in the HAT
medium, but they undergo normal cell death after
some division
•- In hybridoma technology, the myeloma cells used
are HGPRT deficient
•-So these cells can’t survive in HAT medium as
Aminopterine blocks the Denovo pathway

33. cont..
oHybrid cells has HGPRT enzyme from the B
cell as well as they have the ability to
multiply repeatedly as myeloma cells
oSo only hybrid cells can survive in HAT
medium

35. identificAtion And iSolAtion of
the hybridomA cellS
•The first screening technique used is ELISA
•-Done by incubating the hybridoma culture
supernatant, secondary enzyme labeled
conjugate and chromogenic substrate
•-Formation of a coloured product indicates a
positive hybridoma

36. cont…
•Two methods have been used for multiplying
the hybridoma cells
1.In-vivo
2.In-vitro

38. cont…
oIv-vivo procedure involves introduction of
hybridoma cells into the peritoneal cavity of
the animal ,then ascetic fluid is isolated and
then antibodies are isolated from it
oIn-vitro method involves culturing of
hybridoma cells in suitable culture media and
then antibodies are isolated and purified

39. cont..
•Once a hybridoma colony is established, it
will continually grow in culture medium like
RPMI-1640 and produce antibodies

40. multiwell plAteS
•Multiwell plates are used initially to grow the
hybridomas
•After selection, they are changed to tissue culture
flasks
•This provides enough cells for cryopreservation and
supernatant for subsequent investigations
•The supernatant can yield 1 to 60micrograms per ml
which can be maintained at lower temperatures for
future use

41. hybridomA technology in
plAntS

42. monoclonAl AntibodieS in
plAntS
•Aplantibodyis antibody/proteins
producedbygenetically modified crops.
•Uses: as edible vaccines, diagnostic/
therapeutic monoclonal antibodies, for
disease resistance in plants.

44. ApproAch in plAntS

45. PLANT BREEDING BY
SEXUAL CROSS
•Advantages:
New antibody combinations
can be produced.
Dual purpose vaccines can be made.
Properties like enhanced expression, stability, binding
affinity can be achieved using different promoters,
signal sequences.
Mutations in CDRs of V- regions can enhance binding
affinity of antibodies.

46. PLANT TISSUE CULTURE
ADVANTAGES :
•Cell cultures contain fewer biological proteins or molecules
which may contaminate the product.
•Large amounts of proteins obtained in short time & less
purification steps.
•Sexual reproduction is not needed to ensure the lifespan of the
species.
•Transgene stability is also increased.
.

47. APPLICATIONS
Treatment of infectious disease,
inflammation, autoimmune disease or cancer.
Tobacco produced mAb is more viable
alternative to mAb produced in mouse ascites
fluid for the large amounts needed for
purification of hepatitis B vaccine.

48. CONT..
World's first clinically tested plantibody, CaroRx
binds specifically to Streptococcus mutans, the
bacteria that cause tooth decay, and prevents the
bacteria from adhering to teeth.
CaroRx is intended for regular topical preventative
administration by both dental hygienists and patients
allowing a thorough cleaning and intervention for any
existing decay.

49. IMMUNIZATION
Potential proteins
produced are
cytokines, hormones,
enzymes, epidermal
growth
factors, interferons,
and pharmaceutical
foodstuff which are
considered for oral
immunization.

50. FuNCTIONAL
ANTIbOdIeS Need
•Need to be properly folded and assembled.
•Need disulfide bond formation and
glycosylation.
•Glycosylation is different in plants.
•Only mannose is attached-shorter half-life of
Ab.

51. CONCLuSION
Hybridomas are cells that have been engineered to produce a
desired antibody in large amounts, to produce monoclonal
antibodies.
Monoclonal antibodies can be produced in specialized cells
through a technique now popularly known as hybridoma
technology
The advantage of this process is that it can combine the
qualities of the two different types of cells; the ability to grow
continually, and to produce large amounts of pure antibody.

52. Cont..
• Production of monoclonal antibodies
•Selective production of stereospecific monoclonal
antibodies
•Efficient generation of human monoclonal antibodies
for clinical purposes.

53. CONT..
•Hybridoma technology have changed the
paradigm of plant as a food source to so-
called plant bioreactor to produce valuable
recombinant proteins. These include
therapeutic or diagnostic  monoclonal
antibodies, vaccines, and other
biopharmaceutical proteins.

54. ReFeReNCeS
•Monoclonal antibody engineering in
plants
••Andrew Hiatt , Julian K-C. Ma
••Department of Cell Biology, The Scripps Rcsearch Institute, La
Jolla, CA 92037, USA
•Plantibodies: applications, advantages and bottlenecks
•Molecular Biotechnology Unit, John Innes Centre, Norwich
Research Park, Norwich
•NR4 7UH, UK

55. CONT..
• Milstein, C (1999). "The hybridoma revolution: an offshoot of
basic research“
• Nelson, PN; Reynolds, GM; Waldron, EE; Ward, E; Giannopoulos,
K; Murray, PG (2000). "Demystified …: Monoclonal
antibodies". Molecular pathology
•Ghosh, AK; Mason, D Y; Spriggs, A I (1983).
"Immunocytochemical staining with monoclonal antibodies in
cytologically.
•https://www.sciencedirect.com/topics/immunology-and.../hybridoma-
technology
•https://www.ncbi.nlm.nih.gov

56. Department for Molecular Biotechnology, RWTH Aachen,
Worringerweg 1, 52074 Aachen, Germany
PLANTIBODY: AN OVERVIEW( Asian journal of Pharmacy
and Life Science, Vol. 1 (1), Jan-Mar, 2011)
Priya Jain*, Prasoon Pandey, Dheeraj Jain, Pankaj Dwivedi
College of pharmacy, IPS academy, rajendra nagar, Indore,
India. 452012